230 related articles for article (PubMed ID: 12618904)
1. 18F-DOPA positron emission tomography for the detection of glomus tumours.
Hoegerle S; Ghanem N; Altehoefer C; Schipper J; Brink I; Moser E; Neumann HP
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):689-94. PubMed ID: 12618904
[TBL] [Abstract][Full Text] [Related]
2. A family with pheochromocytoma-paraganglioma inherited tumour syndrome. Serial 18F-DOPA PET/CT investigations.
Knie B; Plotkin M; Zschieschang P; Prasad V; Moskopp D
Nuklearmedizin; 2016; 55(1):34-40. PubMed ID: 26740102
[TBL] [Abstract][Full Text] [Related]
3. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
[TBL] [Abstract][Full Text] [Related]
4. (18)F-DOPA PET/CT and MRI: description of 12 histologically-verified pheochromocytomas.
Magnaldi S; Mayerhoefer ME; Khameneh A; Schuetz M; Javor D; Mitterhauser M; Dudczak R; Hacker M; Karanikas G
Anticancer Res; 2014 Feb; 34(2):791-5. PubMed ID: 24511014
[TBL] [Abstract][Full Text] [Related]
5. Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET.
Rischke HC; Benz MR; Wild D; Mix M; Dumont RA; Campbell D; Seufert J; Wiech T; Rössler J; Weber WA; Neumann HP
J Nucl Med; 2012 Sep; 53(9):1352-8. PubMed ID: 22836345
[TBL] [Abstract][Full Text] [Related]
6. 18F-DOPA PET/CT in the evaluation of hereditary SDH-deficiency paraganglioma-pheochromocytoma syndromes.
Marzola MC; Chondrogiannis S; Grassetto G; Rampin L; Maffione AM; Ferretti A; Opocher G; Schiavi F; Colletti PM; Rubello D
Clin Nucl Med; 2014 Jan; 39(1):e53-8. PubMed ID: 23856824
[TBL] [Abstract][Full Text] [Related]
7. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study.
Koopmans KP; de Vries EG; Kema IP; Elsinga PH; Neels OC; Sluiter WJ; van der Horst-Schrivers AN; Jager PL
Lancet Oncol; 2006 Sep; 7(9):728-34. PubMed ID: 16945767
[TBL] [Abstract][Full Text] [Related]
8. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels.
Hoegerle S; Altehoefer C; Ghanem N; Brink I; Moser E; Nitzsche E
Eur J Nucl Med; 2001 Jan; 28(1):64-71. PubMed ID: 11202454
[TBL] [Abstract][Full Text] [Related]
9. Pheochromocytomas: detection with 18F DOPA whole body PET--initial results.
Hoegerle S; Nitzsche E; Altehoefer C; Ghanem N; Manz T; Brink I; Reincke M; Moser E; Neumann HP
Radiology; 2002 Feb; 222(2):507-12. PubMed ID: 11818620
[TBL] [Abstract][Full Text] [Related]
10. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy.
King KS; Chen CC; Alexopoulos DK; Whatley MA; Reynolds JC; Patronas N; Ling A; Adams KT; Xekouki P; Lando H; Stratakis CA; Pacak K
J Clin Endocrinol Metab; 2011 Sep; 96(9):2779-85. PubMed ID: 21752889
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis.
Treglia G; Cocciolillo F; de Waure C; Di Nardo F; Gualano MR; Castaldi P; Rufini V; Giordano A
Eur J Nucl Med Mol Imaging; 2012 Jul; 39(7):1144-53. PubMed ID: 22358431
[TBL] [Abstract][Full Text] [Related]
12. The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma.
Timmers HJ; Hadi M; Carrasquillo JA; Chen CC; Martiniova L; Whatley M; Ling A; Eisenhofer G; Adams KT; Pacak K
J Nucl Med; 2007 Oct; 48(10):1599-606. PubMed ID: 17873132
[TBL] [Abstract][Full Text] [Related]
13. Clinical Value of 18F-fluorodihydroxyphenylalanine Positron Emission Tomography/Contrast-enhanced Computed Tomography (18F-DOPA PET/CT) in Patients with Suspected Paraganglioma.
El-Rabadi K; Weber M; Mayerhofer M; Nakuz T; Scherer T; Mitterhauser M; Dudczak R; Hacker M; Karanikas G
Anticancer Res; 2016 Aug; 36(8):4187-93. PubMed ID: 27466530
[TBL] [Abstract][Full Text] [Related]
14. Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.
Ambrosini V; Tomassetti P; Rubello D; Campana D; Nanni C; Castellucci P; Farsad M; Montini G; Al-Nahhas A; Franchi R; Fanti S
Nucl Med Commun; 2007 Jun; 28(6):473-7. PubMed ID: 17460538
[TBL] [Abstract][Full Text] [Related]
15. Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients.
Kauhanen S; Seppänen M; Minn H; Gullichsen R; Salonen A; Alanen K; Parkkola R; Solin O; Bergman J; Sane T; Salmi J; Välimäki M; Nuutila P
J Clin Endocrinol Metab; 2007 Apr; 92(4):1237-44. PubMed ID: 17227804
[TBL] [Abstract][Full Text] [Related]
16. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma.
Luster M; Karges W; Zeich K; Pauls S; Verburg FA; Dralle H; Glatting G; Buck AK; Solbach C; Neumaier B; Reske SN; Mottaghy FM
Thyroid; 2010 May; 20(5):527-33. PubMed ID: 20450432
[TBL] [Abstract][Full Text] [Related]
18. Head-to-head comparison between
Heimburger C; Veillon F; Taïeb D; Goichot B; Riehm S; Petit-Thomas J; Averous G; Cavalcanti M; Hubelé F; Chabrier G; Namer IJ; Charpiot A; Imperiale A
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):979-987. PubMed ID: 28050631
[TBL] [Abstract][Full Text] [Related]
19. Compared to
Kroiss AS; Uprimny C; Shulkin BL; Frech A; Tilg H; Gasser RW; Sprinzl GM; Gruber L; Thomé C; Plangger C; Url C; Fraedrich G; Virgolini IJ
Ann Nucl Med; 2017 Jun; 31(5):357-365. PubMed ID: 28349331
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.
Beuthien-Baumann B; Strumpf A; Zessin J; Bredow J; Kotzerke J
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1604-9. PubMed ID: 17435996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]